Drug-induced immune thrombocytopenia: pathogenesis, diagnosis, and management
Reads0
Chats0
TLDR
The most important aspects of patient management are a high index of suspicion and a careful history of drug exposure in an individual who presents with acute, often severe thrombocytopenia of unknown etiology.About:
This article is published in Journal of Thrombosis and Haemostasis.The article was published on 2009-06-01 and is currently open access. It has received 280 citations till now.read more
Citations
More filters
Journal ArticleDOI
Approach to the Diagnosis and Management of Drug-Induced Immune Thrombocytopenia
Donald M. Arnold,Ishac Nazi,Theodore E. Warkentin,James W. Smith,Lisa J. Toltl,James N. George,John G. Kelton +6 more
TL;DR: Key features are: the presence of severe thrombocytopenia (platelet nadir <20×10(9)/L); bleeding complications; onset 5 to 10days after first drug exposure, or within hours of subsequent exposures or after first exposure to fibans or abciximab; and exposure to drugs that have been previously implicated in DITP reactions.
Journal ArticleDOI
Heparin-induced thrombocytopenia
TL;DR: Understanding HIT may help unravel why host defenses can trigger autoimmunity, and it is suggested that HIT mimics immunity against repetitive antigens, as they are relevant in microbial defense.
Journal ArticleDOI
Identifying drugs that cause acute thrombocytopenia: an analysis using 3 distinct methods
Jessica A. Reese,Xiaoning Li,Manfred Hauben,Richard H. Aster,Richard H. Aster,Daniel W. Bougie,Daniel W. Bougie,Brian R. Curtis,Brian R. Curtis,James N. George,Sara K. Vesely +10 more
TL;DR: This resource provides a resource for diagnosis of DITP and for drug safety surveillance, and analyzed 3 distinct methods for identifying drugs that may cause thrombocytopenia.
Journal ArticleDOI
Emerging therapeutic opportunities for integrin inhibitors.
TL;DR: In this article, the authors discuss the development of integrin inhibitors, particularly the challenges in developing inhibitors for integrins that contain an α-subunit, and suggest how these challenges could be addressed.
Journal ArticleDOI
A systematic evaluation of laboratory testing for drug-induced immune thrombocytopenia.
Donald M. Arnold,Donald M. Arnold,S. Kukaswadia,Ishac Nazi,A. Esmail,Lori Dewar,James W. Smith,Theodore E. Warkentin,John G. Kelton +8 more
TL;DR: 16 drugs met criteria for a definite laboratory diagnosis of DITP and thus had the highest probability of causing DITE, and may be helpful for ranking potential causes of thrombocytopenia in a given patient.
References
More filters
Journal ArticleDOI
Heparin-induced thrombocytopenia.
Fabrizio Fabris,Guido Luzzatto,Piero Maria Stefani,Bruno Girolami,Giuseppe Cella,Antonio Girolami +5 more
TL;DR: The aim of this article is to review the most recent advances in the field and to give critical guidelines for the clinical diagnosis and treatment of HIT II, the most frequent and dangerous side-effect of heparin therapy.
Journal ArticleDOI
Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity : an explanation for the thrombotic complications of heparin-induced thrombocytopenia
Theodore E. Warkentin,Catherine P.M. Hayward,Lynn K. Boshkov,Aurelio Santos,Jo-Ann I. Sheppard,Arthur P. Bode,John G. Kelton +6 more
TL;DR: Observations indicate that the generation of procoagulant platelet-derived microparticles in vivo is a plausible explanation for the thrombotic complications observed in some patients with heparin-inducedThrombocytopenia.
Journal ArticleDOI
Drug-Induced Immune Thrombocytopenia
TL;DR: The current understanding of pathogenesis is summarized and a guide for diagnosis and management of thrombocytopenia is provided.
Journal ArticleDOI
Drug-Induced Thrombocytopenia: A Systematic Review of Published Case Reports
James N. George,Gary E. Raskob,Shehla Rizvi Shah,Mujahid A. Rizvi,Stephen A. Hamilton,Scott Osborne,Thomas Vondracek +6 more
TL;DR: This systematic review analyzed all published reports of drug-induced thrombocytopenia by using explicit, a priori criteria for establishing levels of evidence of a causal relation to help clinicians better understand the likelihood that a drug will cause throm bocy topenia.
Journal ArticleDOI
Monoclonal antibodies to ligand-occupied conformers of integrin alpha IIb beta 3 (glycoprotein IIb-IIIa) alter receptor affinity, specificity, and function.
TL;DR: Fab fragments of certain antibodies against LIBS on integrin alpha IIb beta 3 (platelet glycoprotein IIb-IIIa) block platelet aggregation, and changes in the conformation of this integrin modulate both the specificity and affinity of ligand recognition.
Related Papers (5)
Drug-induced thrombocytopenia: pathogenesis, evaluation, and management
James N. George,Richard H. Aster +1 more